Skip to Content

Cinvanti Approval History

FDA Approved: Yes (First approved November 9, 2017)
Brand name: Cinvanti
Generic name: aprepitant
Dosage form: Injection
Company: Heron Therapeutics, Inc.
Treatment for: Nausea/Vomiting, Chemotherapy Induced

Cinvanti (aprepitant) is a polysorbate 80 free, intravenous formulation of aprepitant, a substance P/neurokinin-1 (NK 1) receptor antagonist indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV).

Development History and FDA Approval Process for Cinvanti

DateArticle
Feb 26, 2019Approval FDA Approves Supplemental New Drug Application to Expand Cinvanti (aprepitant) Label for IV Push
Nov  9, 2017Approval FDA Approves Cinvanti (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV)
Jan 16, 2017Heron Announces Submission of Cinvanti NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide